Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Heat Shock Protein 90 Inhibitor XL888, Hsp90 Inhibitor XL888
XL888 · 1 trial · 15 indications
Summary statistics will be presented. Toxicities will be presented as worst toxicity per patient and will be reported as percent toxicity.
| Arm | Type | Description |
|---|---|---|
| Treatment (pembrolizumab, XL888) | EXPERIMENTAL | Patients receive pembrolizumab IV over 30 minutes on day 1 and XL888 PO on days 1, 4, 8, 11, 15, and 18. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| XL888 | DRUG | Given PO |
| Pembrolizumab | BIOLOGICAL | Given IV |
Inclusion Criteria: * Patients with stage IV or locally advanced unresectable gastrointestinal adenocarcinomas (gastric, gastroesophageal junction \[GEJ\], cholangiocarcinoma, hepatocellular, pancreas, colorectal, small intestinal tumors) who have failed at least one prior therapy (dose escalation ...
XL888 is an investigational small molecule being studied in colorectal adenocarcinoma and other advanced gastrointestinal cancers. It has been evaluated in a Phase 1 trial in patients with advanced gastrointestinal cancer, including metastatic colorectal and pancreatic adenocarcinoma. It is not an approved therapy and remains in clinical development.
XL888 is developed by Exelixis, Inc., the oncology-focused biopharmaceutical company traded on Nasdaq under the ticker EXEL. Exelixis is the sponsor associated with the clinical development of XL888 in advanced gastrointestinal cancers.
XL888 is in Phase 1 clinical development. Its single recorded trial, NCT03095781, was a Phase 1 study that has been completed. The drug is investigational and has not been approved by the FDA for any indication.
XL888 has been studied in one clinical trial, NCT03095781, titled Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer. The Phase 1 trial enrolled 49 patients in the United States and is completed. It was an uncontrolled, non-randomized study in adults with advanced gastrointestinal cancers.
XL888 was studied in advanced gastrointestinal cancers, including colorectal adenocarcinoma and pancreatic adenocarcinoma. The completed Phase 1 trial NCT03095781 enrolled patients with recurrent, stage III, stage IV, and unresectable forms of these cancers. The study population was not biomarker-selected.